The Centre for Metabolic Bone Disease at Hull Royal Infirmaty provides a high quality service for the detection, prevention and management of osteoporosis. The Centre provides a direct access bone densitometry service and specialist outpatient clinics. Thanks to OSPREY the bone densitometry facilities in the Centre are some of the most up-to-date in the UK consisting of three fan-beam dual-energy X-ray absorptiometry (DXA) scanners, along with peripheral ultrasound and DXA systems.

Selection of Research Publications

Carried out in the Centre for Metabolic Bone Disease at Hull Royal Infirmary with support from OSPREY.

1: Gregson CL, Paggiosi MA, Crabtree N, Steel SA, McCloskey E, Duncan EL, Fan B, Shepherd JA, Fraser WD, Smith GD, Tobias JH. Analysis of body composition in individuals with high bone mass reveals a marked increase in fat mass in women but not men. J Clin Endocrinol Metab. 2013 Feb;98(2):818-28. doi: 10.1210/jc.2012-3342. Epub 2013 Jan 21. PubMed PMID: 23337721; PubMed Central PMCID: PMC3589712.

2: Gregson CL, Sayers A, Lazar V, Steel S, Dennison EM, Cooper C, Smith GD, Rittweger J, Tobias JH. The high bone mass phenotype is characterised by a combined cortical and trabecular bone phenotype: findings from a pQCT case-control study. Bone. 2013 Jan;52(1):380-8. doi: 10.1016/j.bone.2012.10.021.  Epub 2012 Oct 24. PubMed PMID: 23103330; PubMed Central PMCID: PMC3526774.

3: Gregson CL, Steel SA, O'Rourke KP, Allan K, Ayuk J, Bhalla A, Clunie G, Crabtree N, Fogelman I, Goodby A, Langman CM, Linton S, Marriott E, McCloskey E,  Moss KE, Palferman T, Panthakalam S, Poole KE, Stone MD, Turton J, Wallis D, Warburton S, Wass J, Duncan EL, Brown MA, Davey-Smith G, Tobias JH. 'Sink or swim': an evaluation of the clinical characteristics of individuals with high bone mass. Osteoporos Int. 2012 Feb;23(2):643-54. doi: 10.1007/s00198-011-1603-4. Epub 2011 Apr 1. PubMed PMID: 21455762; PubMed Central PMCID: PMC3261396.

4: Middleton ET, Steel SA, Aye M, Doherty SM. The effect of prior bisphosphonate therapy on the subsequent therapeutic effects of strontium ranelate over 2 years. Osteoporos Int. 2012 Jan;23(1):295-303. doi: 10.1007/s00198-011-1547-8. Epub 2011 Jan 28. PubMed PMID: 21274515.

5: Middleton ET, Steel SA, Aye M, Doherty SM. The effect of prior bisphosphonate  therapy on the subsequent BMD and bone turnover response to strontium ranelate. J Bone Miner Res. 2010 Mar;25(3):455-62. doi: 10.1359/jbmr.090821. PubMed PMID: 20201000.

6: Middleton ET, Gardiner ED, Steel SA. Which women should be selected for vertebral fracture assessment? Comparing different methods of targeting VFA. Calcif Tissue Int. 2009 Sep;85(3):203-10. doi: 10.1007/s00223-009-9268-0. Epub 2009 Jul 17. PubMed PMID: 19609737.

7: Thorpe JA, Steel SA. The Alara Metriscan phalangeal densitometer: evaluation and triage thresholds. Br J Radiol. 2008 Oct;81(970):778-83. doi: 10.1259/bjr/69540165. Epub 2008 Jun 30. PubMed PMID: 18591198.

8: Middleton ET, Steel SA. Routine versus targeted vertebral fracture assessment for the detection of vertebral fractures. Osteoporos Int. 2008 Aug;19(8):1167-73. doi: 10.1007/s00198-007-0548-0. Epub 2008 Mar 13. PubMed PMID: 18338099.

9: Middleton ET, Steel SA, Doherty SM. The effect of prior bisphosphonate exposure on the treatment response to teriparatide in clinical practice. Calcif Tissue Int. 2007 Nov;81(5):335-40. Epub 2007 Oct 16. PubMed PMID: 17938845.